Merit Medical Systems, Inc. manufactures and markets disposable medical devices for interventional, diagnostic, and therapeutic procedures in cardiology, radiology, oncology, critical care, and endoscopy. The company operates in two segments, Cardiovascular and Endoscopy. It provides peripheral intervention products for the diagnosis and treatment of diseases in peripheral vessels and organs; and cardiac intervention products, such as access, angiography, hemostasis, intervention, fluid management, electrophysiology and cardiac rhythm management, and hemodynamic monitoring to treat various heart conditions. The company also offers custom procedural solutions that include critical care products, disinfection protection systems, syringes, swab and collection systems, manifold kits, and trays and packs; coated tubes and wires; and sensor components for microelectromechanical systems. In addition, it provides pulmonary products that consist of laser-cut tracheobronchial stents, advanced over-the-wire and direct visualization delivery systems, and dilation balloons; gastroenterology products; and kits and accessories for endoscopy and bronchoscopy procedures. The company sells its products to hospitals and alternate site-based physicians, technicians, and nurses through direct sales force, distributors, original equipment manufacturer partners, or custom procedure tray manufacturers in the United States and internationally. The company was incorporated in 1987 and is headquartered in South Jordan, Utah.
IPO Year:
Exchange: NASDAQ
Website: merit.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/11/2024 | $103.00 → $120.00 | Equal Weight → Overweight | Wells Fargo |
| 6/28/2024 | $96.00 | Outperform | Robert W. Baird |
| 4/11/2024 | $88.00 | Buy | CL King |
| 2/7/2024 | $87.00 | Neutral | BofA Securities |
| 12/21/2023 | $100.00 | Hold → Buy | Canaccord Genuity |
| 12/20/2022 | $73.00 → $72.00 | Buy → Hold | Canaccord Genuity |
| 2/25/2022 | $73.00 → $72.00 | Outperform | Raymond James |
| 2/25/2022 | $83.00 → $73.00 | Buy | Needham |
| 10/29/2021 | $68.00 → $74.00 | Equal-Weight | Wells Fargo |
| 7/30/2021 | $69.00 → $73.00 | Outperform | Raymond James |
144 - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
10-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
10-Q - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
8-K - MERIT MEDICAL SYSTEMS INC (0000856982) (Filer)
At 6 months, the WRAPSODY CIE achieved 89.8% and 72.6% target lesion primary patency and access circuit primary patency, respectively.At 12 months, the WRAPSODY CIE achieved 70.1% and 58.1% target lesion primary patency and access circuit primary patency, respectively. SOUTH JORDAN, Utah, March 25, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that the six-month results from the randomized arm of the WRAPSODY Arteriovenous Access Efficacy (WAVE) trial are scheduled for publication in the April issue of Kidney International. Twelve-month results from the randomized arm of the WAVE trial are scheduled for prese
SOUTH JORDAN, Utah, March 18, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, announced that Chairman and Chief Executive Officer, Fred Lampropoulos, will visit the Nasdaq MarketSite in Times Square to ring the opening bell on Wednesday, March 19, 2025. The ceremony begins at 9:15 A.M. (EDT) and the bell ringing takes place at 9:30 A.M. "Merit's listing on Nasdaq for 35 years marks a significant milestone in our company's history," said Lampropoulos. "Nasdaq has been an exceptional partner, providing Merit with strong execution and visibility within the investor community. We extend our sincere appreciation for Nasdaq's on-goin
SOUTH JORDAN, Utah, March 10, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced enrollment of the first patient in its multicenter, prospective study of the Bloom Micro Occluder System for the treatment of patent ductus arteriosus (PDA) in premature infants (PREEMIE study). PDA is a congenital heart condition that occurs when the ductus arteriosus, a blood vessel connecting the aorta and pulmonary artery, does not close following birth. The condition is common in premature, low-birth-weight infants. A PDA affects the way blood flows through a baby's lungs. A hemodynamically significant or large PDA (hsPDA) can neg
Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4%Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectivelyGAAP operating margin of 10.3%, compared to 10.4% in prior year periodNon-GAAP operating margin* of 19.6%, compared to 16.6% in prior year periodGAAP EPS $0.46, down 2.6%,Non-GAAP EPS* $0.93, up 25.8%, andFree cash flow* generation of $65.3 million, up 18.4% Fiscal Year 2024 Highlights† Reported revenue of $1.357 billion, up 7.9%Constant currency revenue* and constant currency revenue, organic* up 8.5% and up 6.0%, respectivelyGAAP operating margin of 11.5 %, compared to 9.9% in prior yearNon-GAAP opera
2024 preliminary unaudited revenue in the range of approximately $1.355 billion - $1.357 billion, up approximately 7.7% - 7.9% year-over-year2024 preliminary constant currency revenue* increased in the range of approximately 8.4% - 8.6% year over year2024 financial results and 2025 guidance to be released February 25, 2025 * Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial measure to its most directly comparable GAAP financial measure is included under the heading "Non-GAAP Financial Measure" below. SOUTH JORDAN, Utah, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of hea
Unique cell-impermeable1 design extends life-saving treatment for dialysis patientsMerit to host a WRAPSODY informational call on January 28, 2025 SOUTH JORDAN, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that the WRAPSODY® Cell-Impermeable Endoprosthesis has received premarket approval from the US Food and Drug Administration (FDA). With this approval, Merit can begin commercialization of the device in the USA in 2025. WRAPSODY is designed to extend long-term vessel patency in dialysis patients2. Many patients undergoing dialysis rely on a vascular acce
SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Merit's operations or financial performance. Based upon Mr. Wright's resignation, Merit's Board of Directors has re-appointed Fred P. Lampropoulos as Merit's President. ABOUT MERI
SOUTH JORDAN, Utah, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced positive six-month findings from the single-arm AVG cohort of its WRAPSODY Arteriovenous Access Efficacy (WAVE) pivotal trial. The data were presented at the 51st annual VEITHsymposium during the Novel Technologies in Hemodialysis Access session. An AVG is a synthetic tube that is used for long-term access to blood vessels for patients undergoing hemodialysis. However, over time, the graft may become narrow or blocked, resulting in potentially life-threatening consequences. Merit's WRAPSODY Cell-Impermeable Endoprosthesis is designe
SOUTH JORDAN, Utah, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader in healthcare technology, today reported that it has completed the acquisition of Cook Medical's lead management portfolio. The purchase consideration consisted of a cash payment of approximately $210 million and the assumption of certain liabilities. Merit funded the acquisition payment through a combination of cash on hand and borrowings under its long-term credit facility. "We are pleased to announce the completion of this important acquisition," said Fred P. Lampropoulos, Merit's Chairman and Chief Executive Officer. "We are excited to welcome the talented team from Cook Me
Third Quarter 2024 Highlights† Reported revenue of $339.8 million, up 7.8%Constant currency revenue* and constant currency revenue, organic* up 7.9% and up 5.7%, respectivelyGAAP operating margin of 11.0%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.2%, compared to 17.4% in prior year periodGAAP EPS $0.48, up 8.0%, and non-GAAP EPS* $0.86, up 21.1%Generated free cash flow* $120 million over the first nine months of 2024, up 116% year-over-yearCompleted the acquisition of certain assets from EndoGastric Solutions, Inc., which included the EsophyX® Z+, a device intended for the treatment of chronic gastroesophageal reflux diseaseAnnounced positive 6-month findings
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
4 - MERIT MEDICAL SYSTEMS INC (0000856982) (Issuer)
For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r
Wells Fargo upgraded Merit Medical from Equal Weight to Overweight and set a new price target of $120.00 from $103.00 previously
Robert W. Baird initiated coverage of Merit Medical with a rating of Outperform and set a new price target of $96.00
CL King initiated coverage of Merit Medical with a rating of Buy and set a new price target of $88.00
BofA Securities initiated coverage of Merit Medical with a rating of Neutral and set a new price target of $87.00
Canaccord Genuity upgraded Merit Medical from Hold to Buy and set a new price target of $100.00
Canaccord Genuity downgraded Merit Medical from Buy to Hold and set a new price target of $72.00 from $73.00 previously
Raymond James reiterated coverage of Merit Medical Systems with a rating of Outperform and set a new price target of $72.00 from $73.00 previously
Needham reiterated coverage of Merit Medical Systems with a rating of Buy and set a new price target of $73.00 from $83.00 previously
Wells Fargo reiterated coverage of Merit Medical Systems with a rating of Equal-Weight and set a new price target of $74.00 from $68.00 previously
Raymond James reiterated coverage of Merit Medical Systems with a rating of Outperform and set a new price target of $73.00 from $69.00 previously
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13D/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G/A - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SC 13G - MERIT MEDICAL SYSTEMS INC (0000856982) (Subject)
SOUTH JORDAN, Utah, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI) ("Merit" or the "Company"), a global leader of healthcare technology, today announced the resignation of its President, Joseph C. Wright, effective January 3, 2025. The Company noted that prior to Mr. Wright's resignation, Merit had received notice of allegations regarding his conduct, which Merit's independent directors investigated with the assistance of independent counsel. The allegations were unrelated to Merit's operations or financial performance. Based upon Mr. Wright's resignation, Merit's Board of Directors has re-appointed Fred P. Lampropoulos as Merit's President. ABOUT MERI
SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced that its shareholders elected Silvia M. Perez, President of the Commercial Branding and Transportation Division at 3M Company, as a director in Merit's Annual Meeting of Shareholders held on May 15, 2024. Merit's shareholders also re-elected Fred P. Lampropoulos and Stephen C. Evans as directors. Ms. Perez and Messrs. Lampropoulos and Evans were elected to serve three-year terms. "We are pleased to welcome Silvia Perez as our newest director," said Mr. Lampropoulos, Merit's Chairman and Chief Executive Officer. "Her expertise and proven
Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports "Continued Growth Initiatives" Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immediately. As President, Mr. Wright will be responsible for the oversight of Merit's global commercial, marketing, and manufacturing operations. Mr. Wright has been an instrumental part of the Merit team over the past 19 years. He most recently served as Chief Commercial Officer, where he led the development and expansion of Merit's global commercial activit
SOUTH JORDAN, Utah, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, today outlined the ongoing succession planning process for its Chief Executive Officer (CEO). Pursuant to an Amended and Restated Employment Agreement, effective June 8, 2023, Merit founder, CEO, and President, Fred Lampropoulos, will continue to serve as Merit's CEO and President through December 31, 2025. To carry out its responsibility for CEO succession, the Merit Board of Directors appointed a special steering committee of independent directors led by Ann Millner, Ed.D., Lead Independent Director. The committee is deve
SOUTH JORDAN, Utah, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, today announced the appointment of Merit's long-time executive, Joe Wright, as Merit's Chief Commercial Officer. In this role, Joe will be responsible for spearheading the company's overall commercial strategy. Joe's career at Merit began over seventeen years ago. Highly regarded for his deep international experience, Joe recently was the President of International leading business units across APAC and the Americas. For the past year, he also had commercial responsibility for EMEA. His previous positions include serving as P
Fourth Quarter Highlights† Reported revenue of $355.2 million, up 9.4%Constant currency revenue* and constant currency revenue, organic* up 10.1% and up 6.1%, respectivelyGAAP operating margin of 10.3%, compared to 10.4% in prior year periodNon-GAAP operating margin* of 19.6%, compared to 16.6% in prior year periodGAAP EPS $0.46, down 2.6%,Non-GAAP EPS* $0.93, up 25.8%, andFree cash flow* generation of $65.3 million, up 18.4% Fiscal Year 2024 Highlights† Reported revenue of $1.357 billion, up 7.9%Constant currency revenue* and constant currency revenue, organic* up 8.5% and up 6.0%, respectivelyGAAP operating margin of 11.5 %, compared to 9.9% in prior yearNon-GAAP opera
2024 preliminary unaudited revenue in the range of approximately $1.355 billion - $1.357 billion, up approximately 7.7% - 7.9% year-over-year2024 preliminary constant currency revenue* increased in the range of approximately 8.4% - 8.6% year over year2024 financial results and 2025 guidance to be released February 25, 2025 * Constant currency revenue is a non-GAAP financial measure. A reconciliation of this financial measure to its most directly comparable GAAP financial measure is included under the heading "Non-GAAP Financial Measure" below. SOUTH JORDAN, Utah, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of hea
Unique cell-impermeable1 design extends life-saving treatment for dialysis patientsMerit to host a WRAPSODY informational call on January 28, 2025 SOUTH JORDAN, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that the WRAPSODY® Cell-Impermeable Endoprosthesis has received premarket approval from the US Food and Drug Administration (FDA). With this approval, Merit can begin commercialization of the device in the USA in 2025. WRAPSODY is designed to extend long-term vessel patency in dialysis patients2. Many patients undergoing dialysis rely on a vascular acce
SOUTH JORDAN, Utah, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader in healthcare technology, today reported that it has completed the acquisition of Cook Medical's lead management portfolio. The purchase consideration consisted of a cash payment of approximately $210 million and the assumption of certain liabilities. Merit funded the acquisition payment through a combination of cash on hand and borrowings under its long-term credit facility. "We are pleased to announce the completion of this important acquisition," said Fred P. Lampropoulos, Merit's Chairman and Chief Executive Officer. "We are excited to welcome the talented team from Cook Me
Third Quarter 2024 Highlights† Reported revenue of $339.8 million, up 7.8%Constant currency revenue* and constant currency revenue, organic* up 7.9% and up 5.7%, respectivelyGAAP operating margin of 11.0%, compared to 11.1% in prior year periodNon-GAAP operating margin* of 19.2%, compared to 17.4% in prior year periodGAAP EPS $0.48, up 8.0%, and non-GAAP EPS* $0.86, up 21.1%Generated free cash flow* $120 million over the first nine months of 2024, up 116% year-over-yearCompleted the acquisition of certain assets from EndoGastric Solutions, Inc., which included the EsophyX® Z+, a device intended for the treatment of chronic gastroesophageal reflux diseaseAnnounced positive 6-month findings
SOUTH JORDAN, Utah, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended September 30, 2024, after the close of the stock market on Wednesday, October 30, 2024. Merit will hold its investor conference call on the same day (Wednesday, October 30, 2024) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide dec
Second Quarter 2024 Highlights† Reported revenue of $338.0 million, up 5.6%Constant currency revenue* up 6.6%Constant currency revenue, organic,* up 5.0%GAAP operating margin of 13.6%, compared to 9.0% in prior year periodNon-GAAP operating margin* of 20.1%, compared to 19.1% in prior year periodGAAP EPS $0.61, up 75.7%Non-GAAP EPS* $0.92, up 16.8% † Comparisons noted in the bullet points are calculated for the current quarter compared with the same prior year period unless otherwise specified. * The constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and
Asset acquisition expands Merit's endoscopy portfolio with a minimally invasive solution for patients suffering from chronic gastroesophageal reflux disease (GERD). Asset acquisition projected to add approximately $30 million of revenue, on an annualized basis, in key gastrointestinal endoscopy market that leverages existing commercial footprint. Merit reaffirms full-year 2024 financial guidance on standalone basis and updates full-year 2024 financial guidance to include projected partial-year impact from this acquisition. SOUTH JORDAN, Utah, July 01, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a global leader of healthcare technology, today announ
SOUTH JORDAN, Utah, June 18, 2024 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended June 30, 2024, after the close of the stock market on Thursday, August 1, 2024. Merit will hold its investor conference call on the same day (Thursday, August 1, 2024) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific). To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details. A live webcast and slide deck can be accessed
Q1 2024 reported revenue of $323.5 million, up 8.7% compared to Q1 2023Q1 2024 constant currency revenue* up 9.3% compared to Q1 2023Q1 2024 constant currency revenue, organic* up 7.0% compared to Q1 2023Q1 2024 GAAP operating margin of 11.1%, compared to 8.9% in Q1 2023Q1 2024 non-GAAP operating margin* of 17.3%, compared to 16.1% in Q1 2023Q1 2024 GAAP EPS $0.48, up 35.5%, compared to $0.36 in Q1 2023Q1 2024 non-GAAP EPS* $0.77, up 18.7%, compared to $0.64 in Q1 2023 * Constant currency revenue; constant currency revenue, organic; non-GAAP gross profit and margin; non-GAAP operating income and margin; non-GAAP net income; non-GAAP EPS; and free cash flow are non-GAAP financial measures. A